1 / 16

The Global Fund and the Affordable Medicine Facility-malaria (AMF-m)

Learn about the efforts of The Global Fund and the Affordable Medicine Facility-malaria (AMF-m) in fighting malaria, including their strategies, challenges, and achievements.

Télécharger la présentation

The Global Fund and the Affordable Medicine Facility-malaria (AMF-m)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Global Fund and the Affordable Medicine Facility-malaria (AMF-m) Dr Stefano Lazzari Senior Health Advisor The Global Fund to Fight AIDS, Tuberculosis and Malaria APPMG London 9 October 2007

  2. The new context of malaria control • After decades of neglect, there is renewed interest in malaria • This has led to establishment of major global initiatives including the RBM Partnership in 1998, the Global Fund in 2002 and the US President Malaria Initiative in 2005. • An effective, integrated strategy has been developed, based on evidence-based approaches and taking advantage of new technical solutions. The strategy is based on a combination of: • Indoor residual spraying (IRS), • Long-lasting insecticide treated nets (LLINs), • Intermittent preventive treatment for pregnant women (IPTp), • Effective treatment for malaria according to the national treatment guidelines • The importance of strengthening health systems and of the role of non-public sectors in the delivery of interventions has been fully ecognized.

  3. Challenges • Strengthen national malaria programs while also addressing health systems bottlenecks to malaria control. • Ensure the continuous availability of essential commodities, including drugs, diagnostics and LLINs. • Make optimal use of the non-governmental and private sector • Achieve universal access to prevention and treatment by the population at risk, including the rural poor. • Delay the emergence of drug resistance • Ensure sustainable, long-term financing • Continue the research and development of new drugs, diagnostics and effective vaccines • Coordinate efforts, align with national priorities and harmonize international support

  4. Raise it Prove it The Global Fund is an independent public-private partnership mandated:- To raise and to disbursesubstantial new funds - To operate transparently and accountably- To achieve sustained impact on HIV/AIDS, TB, and malaria What is the Global Fund? Spend it BG/290607/1

  5. Guiding Principles • Operate as a financial instrument, not an implementing entity • Make available and leverage additional financial resources • Support programs that reflect national ownership • Operate in a balanced manner in terms of different regions, diseases and interventions • Pursue an integrated and balanced approach to prevention and treatment • Evaluate proposals through independent review processes • Establish a simplified, rapid and innovative grant-making process and operate transparently, with accountability BG/290607/2

  6. ResourcesSeptember 2007 Funding to the Global Fund • Total pledges available through 2008 = US$ 10 billion • Approximately US$ 8.6 billion has been paid in Global Fund funds approved and disbursed • Total proposals approved • 2-year budget of US$ 4.7 billion • 5-year budget of US$ 11.7 billion (proposed total) • Grant agreements signed • 2-year agreement of US$ 4.4 billion • Phase 2 agreement of US$ 2.4 billion • US$4.4 billion disbursed BG/011007/5

  7. The Global Fund and malaria • In 6 rounds the Global Fund has approved funding for 117 malaria grants in 85 countries (41 in Africa). • To date, $2,600 million has been approved and $ 950 million disbursed. Malaria grants represent 22% of the GF portfolio. • Support provided for the initial two years includes: • ACTs: $285 million • ITNs: $109 million • IRS: $ 82 million • Commodities represent about 40% of GF malaria grants

  8. GF malaria grants performance

  9. Initial results in malaria prevention Tanzania: In pilot districts ITN coverage has reached 60%, resulting in under-5 mortality decline of up to 50% Zambia: Distribution of 900,000 ITNs and access to ACTs has resulted in 90% decline in malaria deaths. Lubombo region of Southern Africa: A multi-country programme has contributed to 90% reduction in malaria incidence and 53-94% reduction in malaria prevalence in some areas. Kenya: LLNI coverage rose from 7% in 2004 to 67% in 2005. This was associated with a 44% reduction in child mortality. Rwanda: Reports of rapid decrease in ospitalization in pediatric wards and reduced uptake of ACTs associated with increased coverage with ITNs.

  10. Barriers to scaling-up ACTs • High cost • Limited number of products and manufacturers • Prescription Only Drug • Only available (fully subsidized) in public health facilities with limited coverage of population • Prescribers and consumers habits

  11. Rationale: to increase the availability of ACTs and replace monotherapies across all sectors Note: Other category includes MQ, AQ, and others. ACT data based on WHO estimates and manufacturer interviews. Source: Biosynthetic Artemisinin Roll-Out Strategy, BCG/Institute for OneWorld Health, WHO, Dalberg.

  12. AMF-m +2 years A scenario for ACTs coverage taking into consideration the different sub-sectors, the impact of prevention and the expansion of home-based care Malaria cases prevented CQ or SP CQ or SP CQ or SP CQ or SP ACTs ACTs Coverage by ACTs ACTs ACTs Total malaria treatments = 440 million ACT treatments = 286 million ACT coverage = 65% Home-based treatment of malaria

  13. AMF-m Objectives • Increase the overall use of ACTs and drive out monotherapies and ineffective drugs from the market by: • Reducing end-user prices to an affordabel level through a properly supported global subsidy of ex-manufacturer prices (CIF basis) – in line with IOM recommendations • Introducing (in country) supporting interventions, including the support for the proper use of ACTs.

  14. Benefits of the AMF-m • Ensure a regular supply of cheap and effective antimalarial drugs to all sectors • Facilitate the involvement of the private sector in ACT distribution • Promote, through the supporting interventions, the strengthening of national capacities in • Procurement and drug management, • Drug quality assurance • Pharmacovigilance • Drug resistance monitoring. • Improve forecast of ACT needs, stabilize the ACT market and reduce ACT price.

  15. Several issues still need to be addressed • Improved analysis of what the facility can actually achieve, in what timeframe and at what cost. • Approach to defining, managing and financing of supporting interventions for a “responsible introduction” of the facility. • Making sure that the benefits of the facility are carried forward to the consumer, the rural poor in particular. • Definition of operational model for distribution of ACTs through the informal private sector (through further operational research) • Definition of a clear operational model for price negotiation with manufacturers, that would reduce prices while encouraging innovation and the entry of new manufacturer in the ACT market. • Sources and sustainability of financing for the AMF-m.

  16. Global ACT Subsidy / Affordable Medicines Facility - malariaPSC Discussion Summary • RBM Partnership has requested the Global Fund to consider hosting the AMF-m • Initial analysis shows strong complementarity and potential synergies of between Global Fund and AMF-m objectives and design. • Global Fund Board to consider at its November meeting whether to support hosting the subsidy as an integrated business line within the Global Fund

More Related